The Effect of Xevinapant Combined with Ionizing Radiation on HNSCC and Normal Tissue Cells and the Impact of Xevinapant on Its Targeted Proteins cIAP1 and XIAP

The poor prognosis of HNSCC is partly due to treatment resistance. The SMAC mimetic Xevinapant is a promising new approach to targeted cancer therapy. Xevinapant inhibits cIAP1/2 and XIAP, leading to apoptosis, necroptosis and inhibition of prosurvival signaling. Combining Xevinapant with IR could i...

Full description

Bibliographic Details
Main Authors: Julia Fleischmann, Laura S. Hildebrand, Lukas Kuhlmann, Rainer Fietkau, Luitpold V. Distel
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Cells
Subjects:
Online Access:https://www.mdpi.com/2073-4409/12/12/1653